Skip to main content

Table 1 Basic characteristics of eligible studies

From: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Trial Drug Dose(s) analysed Median follow-up duration (years) ClinicalTrials.gov unique identifier Total number of trial participants Age (years), mean Male, n (%) Patients with a history of DM, n (%) Patients with a history of CKD, n (%) Patients with a history of HF, n (%) Patients with a history of AF, n (%)
Bailey et al. [28] Dapagliflozin 2.5 mg, 5 mg, 10 mg
(once daily)
2.0 NCT00528879 546 53.9 292 (53.5%) 546 (100%) NA NA NA
Bailey et al. [29] Dapagliflozin 2.5 mg, 5 mg, 10 mg
(once daily)
2.0 NCT00528372 558 52.2 276 (49.5%) 558 (100%) NA NA NA
Bode et al. [30] Canagliflozin 100 mg, 300 mg
(once daily)
2.0 NCT01106651 714 63.6 396 (55.5%) 714 (100%) NA NA NA
CANTATA-MSU [31] Canagliflozin 100 mg, 300 mg
(once daily)
1.0 NCT01106625 469 56.7 239 (51.0%) 469 (100%) NA NA NA
CANVAS Program [32] Canagliflozin 100 mg, 300 mg
(once daily)
2.4 NCT01032629; NCT01989754 10,142 63.3 6509 (64.2%) 10,142 (100%) 1774 (17.5%) 1461 (14.4%) 612 (6.0%)
Cefalu et al. [33] 2015 Dapagliflozin 10 mg
(once daily)
1.0 NCT01031680 922 62.9 624 (68.3%) 922 (100%) NA NA NA
CREDENCE [47] Canagliflozin 100 mg
(once daily)
2.6 NCT02065791 4401 63.0 2907 (66.1%) 4401 (100%) 4401 (100%) 652 (15.8%) NA
DAPA-HF [49] Dapagliflozin 10 mg
(once daily)
1.5 NCT03036124 4744 66.3 3635 (76.6%) 1983 (41.8%) 1926 (40.6%) 4744 (100%) 1818 (38.3%)
DECLARE-TIMI 58 [34] Dapagliflozin 10 mg
(once daily)
4.2 NCT01730534 17,160 63.9 10,738 (62.6%) 17,160 (100%) 8997 (52.4%) 1724 (10.0%) 1116 (6.5%)
EMPA-HEART
CardioLink-6 [35]
Empagliflozin 10 mg
(once daily)
0.5 NCT02998970 97 64.0a 90 (92.8%) 97 (100%) 2 (2.1%) 6 (6.2%) NA
EMPA-REG OUTCOME [36] Empagliflozin 10 mg, 25 mg
(once daily)
3.1 NCT01131676 7020 63.1 5016 (71.5%) 7020 (100%) 5480 (78.1%) 706 (10.1%) 389 (5.5%)
EMPA-REG RENAL [45] Empagliflozin 10 mg, 25 mg
(once daily)
1.0 NCT01164501 738 63.9 430 (58.3%) 738 (100%) 738 (100%) NA NA
EMPA-RESPONSE-AHF [48] Empagliflozin 10 mg
(once daily)
0.1 NCT03200860 79 76a 53 (67.1%) 26 (32.9%) NA 79 (100%) 56 (70.9%)
Inagaki et al. [37] Canagliflozin 50 mg, 100 mg, 200 mg, 300 mg
(once daily)
0.3 NCT01022112 383 57.4 261 (68.1%) 383 (100%) 29 (7.6%) NA NA
Kovacs et al. [40] Empagliflozin 10 mg, 25 mg
(once daily)
1.3 NCT01210001 498 54.5 241 (48.4%) 498 (100%) NA NA NA
Leiter et al. [38] Dapagliflozin 10 mg
(once daily)
1.0 NCT01042977 962 63.8 644 (66.9%) 962 (100%) NA 152 (15.8%) NA
Mathieu et al. [41] Dapagliflozin 10 mg
(once daily)
0.5 NCT01646320 320 55.1 146 (45.6%) 320 (100%) NA NA NA
Rosenstock et al. [39] Empagliflozin 10 mg, 25 mg
(once daily)
1.5 NCT01011868 494 58.8 276 (55.9%) 494 (100%) NA NA NA
Softeland et al. [42] Empagliflozin 10 mg, 25 mg
(once daily)
0.5 NCT01734785 332 55.2 198 (59.6%) 332 (100%) 166 (50.0%) NA NA
VERTIS RENAL [46] Ertugliflozin 5 mg, 15 mg (once daily) 1.0 NCT01986855 467 67.3 231 (49.5%) 467 (100%) 467 (100%) NA NA
Wilding et al. [43] Dapagliflozin 2.5 mg, 5 mg, 10 mg (once daily) 1.0 NCT00673231 800 59.3 382 (47.8%) 800 (100%) NA NA NA
Yale et al. [44] Canagliflozin 100 mg, 300 mg (once daily) 1.0 NCT01064414 269 68.5 163 (60.6%) 269 (100%) 269 (100%) NA NA
  1. DM diabetes mellitus, CKD chronic kidney disease, HF heart failure, AF atrial fibrillation, NA not available
  2. aMedian